Where Travere Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Travere Therapeutics (NASDAQ:TVTX) has been analyzed by 14 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target increased by 11.37% to $19.79. Recent analyst actions include both raises and lowers in price targets, reflecting mixed sentiments. Travere's financials show a positive revenue trend but challenges in ROE and ROA, with a high debt-to-equity ratio.
September 27, 2024 | 6:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Travere Therapeutics has received mixed analyst ratings, with an average price target increase of 11.37% to $19.79. The company shows strong revenue growth but faces challenges with ROE, ROA, and a high debt-to-equity ratio.
The mixed analyst ratings and increased price target suggest a neutral short-term impact on TVTX's stock price. While the revenue growth is positive, the challenges in ROE, ROA, and high debt levels may offset potential gains, leading to a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100